A new research has stated that change a protein in the brain could help control Alzheimer's disease. The study by Temple University's School of Medicine has exposed that a protein called 5-lipoxygenase has been found to play a dogmatic role in the formation of the amyloid beta in the brain, the main component of plaques concerned in the development of Alzheimer's disease. The researchers also found that inhibitors of this protein now used to control asthma could perhaps be used to prevent or treat Alzheimer's disease. According to Domenico Pratico, an connect professor of pharmacology in Temple's School of Medicine and the study's guide researcher, the 5-Lipoxygenase enzyme is found in profusion mainly in the region of the brain, the hippocampus, involved in memory.
"What we found was 5-lipoxygenase regulates and reins the amount of total amyloid beta formed in the brain. With age, the more 5-lipoxygenase you have the more amyloid beta you are going to produce. This will translate into an advanced risk to develop full Alzheimer's," said Praticr. An earlier study by Praticr, in which researchers irritated a mouse model of Alzheimer's with a mouse that did not genetically feature 5-lipoxygenase, established that a lack of this enzyme protein alone can decrease the amount of disease in the brain by up to half. Praticr said that the key in the course was 5-lipoxygenase's direct control over the gamma secretase, the only basis of amyloid beta in the brain.
"If you can adapt this enzyme easily, then you can control the amount of total amyloid beta that is formed by the gamma secretase in the brain, thus scheming the amount of Alzheimer's disease," he said. He said that there are some FDA-approved 5-lipoxygenase inhibitors currently being used for the treatment of asthma, and that the Temple researchers experienced some of these inhibitors in the lab against the production of amyloid beat with original positive results. "These drugs are already on the market, they are inexpensive and, most prominently, they are already FDA-approved, so you would not need to go through a strong drug discovery process.
useful links : transport rankings
"What we found was 5-lipoxygenase regulates and reins the amount of total amyloid beta formed in the brain. With age, the more 5-lipoxygenase you have the more amyloid beta you are going to produce. This will translate into an advanced risk to develop full Alzheimer's," said Praticr. An earlier study by Praticr, in which researchers irritated a mouse model of Alzheimer's with a mouse that did not genetically feature 5-lipoxygenase, established that a lack of this enzyme protein alone can decrease the amount of disease in the brain by up to half. Praticr said that the key in the course was 5-lipoxygenase's direct control over the gamma secretase, the only basis of amyloid beta in the brain.
"If you can adapt this enzyme easily, then you can control the amount of total amyloid beta that is formed by the gamma secretase in the brain, thus scheming the amount of Alzheimer's disease," he said. He said that there are some FDA-approved 5-lipoxygenase inhibitors currently being used for the treatment of asthma, and that the Temple researchers experienced some of these inhibitors in the lab against the production of amyloid beat with original positive results. "These drugs are already on the market, they are inexpensive and, most prominently, they are already FDA-approved, so you would not need to go through a strong drug discovery process.
useful links : transport rankings
No comments:
Post a Comment